Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · QuidelOrtho (QDEL)

QuidelOrtho sees Q1 2026 revenue of $615-$620 million on weak respiratory season

Negative Impact 4 of 5 guidance Written later

QuidelOrtho preliminarily estimated first-quarter 2026 revenue at $615-$620 million, citing a weaker respiratory season, slower China distributor sales and delayed EMEA orders. The company said only the low end of its full-year 2026 guidance remains achievable, and that its guidance ranges were intentionally broad.

Key points

  • Preliminary unaudited Q1 2026 revenue (quarter ended March 29, 2026) of $615-$620 million
  • U.S. influenza-like illness visits were down approximately 30% versus Q1 2025, per the CDC
  • Q1 2026 free cash flow expected to be $(65) to $(70) million negative; full-year free cash flow still expected to be positive
  • Full first-quarter results and full-year guidance discussion scheduled for May 5, 2026

The filing

CompanyQuidelOrtho (QDEL)
Form8-K, current report
Filed with the SECApr 15, 2026, 4:15 PM ET
Accession number0001906324-26-000013

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.